Yuvraj_pawp, Author at Pharma Advancement

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer

19th November 2015

Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer MacroGenics,...

Boehringer Ingelheim named one of the most innovative companies worldwide

by Yuvraj_pawp

19th November 2015

Ingelheim, 16 November 2015 - Boehringer Ingelheim has been named one of the most innovative companies worldwide in 2015. For...

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

by Yuvraj_pawp

19th November 2015

First data from post-marketing surveillance was consistent with the safety profile of OFEV® from the clinical studies supporting its FDA...

Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs

by Yuvraj_pawp

19th November 2015

• 11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro...

Time is of the essence for millions living with ‘neglected’ lung disease

by Yuvraj_pawp

19th November 2015

Your Time campaign calls for earlier action in COPDWHO expects COPD to be the third leading cause of death worldwide...

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

by Yuvraj_pawp

19th November 2015

Collaborations aim to speed research and development approaches in Crohn’s disease and ulcerative colitisIcahn School of Medicine, Massachusetts General Hospital,...

Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

by Yuvraj_pawp

19th November 2015

Phase III clinical trial for BI695501, a biosimilar candidate for AbbVie’s Humira®, fully enrolledRecently announced Phase I trial results show...

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

by Yuvraj_pawp

19th November 2015

Brigham and Women’s Hospital in Boston, U.S., and Boehringer Ingelheim announce the results of a new interim analysis from a...

Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound

by Yuvraj_pawp

19th November 2015

• First patients enrolled in pivotal Phase II global trial evaluating BI 1482694 (HM61713) in patients with T790M mutation-positive NSCLC•...

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®

by Yuvraj_pawp

19th November 2015

Studies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD...

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Yuvraj_pawp

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer

Boehringer Ingelheim named one of the most innovative companies worldwide

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs

Time is of the essence for millions living with ‘neglected’ lung disease

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®

Qucik Links

About Us

Subscribe Us

System

Resources

Retrieve your password